Business Wire

AMP Raises $91 Million in Series D Funding to Revolutionize Waste

5.12.2024 15:00:00 CET | Business Wire | Press release

Share

Latest investment to support expansion to process municipal solid waste and single-stream recycling at scale

AMP Robotics Corp. (“AMP”), a leading provider of AI-powered sortation at scale for the waste and recycling industry, has raised $91 million in corporate equity in a Series D financing led by Congruent Ventures. The round featured participation from current and new investors, including Sequoia Capital, XN, Blue Earth Capital, Liberty Mutual Investments, California State Teachers Retirement System (CalSTRS), Wellington Management, Range Ventures, and Tao Capital Partners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205769962/en/

AMP will use the latest funding to accelerate the deployment of its AMP ONE™ systems. AMP ONE provides a full-scale facility solution to sort various material streams and capture more of the billions of dollars in value otherwise lost to landfills or incinerated annually. (Photo: Business Wire)

AMP will use the latest funding to accelerate the deployment of its AMP ONE™ systems, which are capable of cost-effectively sorting municipal solid waste (MSW), as demonstrated by the first-of-its-kind system AMP operates in Portsmouth, Virginia. Last month, AMP also entered into an agreement with Waste Connections, Inc. (TSX/NYSE: WCN) to equip and operate one of Waste Connections’ single-stream recycling facilities in Colorado. AMP ONE provides a full-scale facility solution to sort various material streams and capture more of the billions of dollars in value otherwise lost to landfills or incinerated annually.

“Recycling rates have stagnated in the United States, despite the positive benefits recycling offers local economies and the environment,” said Matanya Horowitz, founder of AMP. “This latest investment enables us to tackle larger projects and deliver real outcomes for waste companies and municipalities – by lowering sortation costs, capturing more material value, diverting organic waste, and extending landfill life – all while helping the industry optimize its strategic assets.”

AMP’s AI uses deep learning to continuously train itself by processing millions of material images into data. The software uses pattern recognition of colors, textures, shapes, sizes, and logos to identify recyclables and contaminants in real time, enabling new offtake chemistries and capabilities. AMP’s first products were a series of sorting robots deployed with minimal retrofit into existing recycling facilities. The company then pioneered a series of next-generation, transformative recycling facilities. With near-zero manual sorting, unprecedented reliability, and pervasive data, these facilities make the recovery of commodities safer and more cost-effective than ever and have grown to encompass MSW sorting, an offering out of reach to the industry prior to the advent of AMP’s technology.

Abe Yokell, co-founder and managing partner of Congruent Ventures, said, “AMP’s AI sortation systems enable consumers to recycle both with and without curbside separation and communities to benefit from the recovery of recycled commodities while reducing dependence on landfills. AMP is an example of the real-world impacts of AI; solutions like AMP’s will divert billions of tons of recyclable material from landfills while reducing emissions.”

Tim Stuart, chief executive officer for AMP, added, “AMP provides meaningfully lower-cost, higher-performance systems to recover commodities and increase landfill diversion, and we’re uniquely positioned to reshape the waste and recycling landscape at a critical time. We’re grateful to our longstanding and newest investors for their support in helping us chart a new path for sustainable materials management and resource efficiency.”

AMP recently augmented its leadership team with the appointment of Stuart, former chief operating officer for Republic Services Inc. (NYSE: RSG). Horowitz transitioned into the role of chief technology officer.

About AMP™

AMP is applying AI-powered sortation at scale to modernize the world's recycling infrastructure and maximize the value in waste. AMP gives waste and recycling leaders the power to harness AI to reduce labor costs, increase resource recovery, and deliver more reliable operations. The company’s AI platform has identified 150 billion items and guided the sortation of more than 2.5 million tons of recyclables. With three full-scale facilities and more than 400 AI systems deployed across North America, Asia, and Europe, AMP’s technology offers a transformational solution to waste sortation and changes the fundamental economics of recycling.

About Congruent Ventures

Congruent Ventures is a leading early-stage venture firm focused on partnering with entrepreneurs to build companies addressing climate and sustainability challenges across four themes: Mobility and Urbanization, the Energy Transition, Food and Agriculture, and Sustainable Production and Consumption. The firm has more than $1 billion in AUM across early-stage climate tech funds, making it one of the largest climate portfolios in early-stage venture. With 59 companies in the portfolio, Congruent is amongst the most active investors in the climate and sustainability ecosystem.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241205769962/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye